Enliven Therapeutics (ELVN) closed at $48.80 on November 13, 2026, up 1.0% from the previous close, on volume of 921,165 shares (30-day average 1,488,409).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Calendar Call Spread | 18-Dec-26 : 15-Jan-27 45 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Fri, 13-Nov 9:37 AM ET)
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
PRNewswire (Thu, 5-Nov 4:05 PM ET)
PRNewswire (Wed, 14-Oct 4:30 PM ET)
PRNewswire (Tue, 6-Oct 4:06 PM ET)
Enliven Therapeutics to Present at Upcoming Investor Conferences
PRNewswire (Thu, 3-Sep 4:05 PM ET)
PRNewswire (Mon, 31-Aug 6:06 PM ET)
ELVN-001 Shows Promising Phase 1 Results, FDA Alignment Paves Way for Phase 3 ENABLE-2 Trial
Market Chameleon (Thu, 11-Jun 6:32 AM ET)
Market Chameleon (Thu, 11-Jun 5:04 AM ET)
Market Chameleon (Fri, 9-Jan 6:14 AM ET)
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.
As of November 13, 2026, ELVN stock price climbed to $48.80 with 921,165 million shares trading.
ELVN has a beta of 0.62, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.01 to the broad based SPY ETF.
ELVN has a market cap of $3.49 billion. This is considered a Mid Cap stock.
In the last 3 years, ELVN traded as high as $62.32 and as low as $9.80.
The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ELVN has outperformed the market in the last year with a price return of +140.7% while the SPY ETF gained +13.4%. However, in the short term, ELVN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.9% vs -2.8% return in SPY. But in the last 2 weeks, ELVN shares have fared better than the market returning +10.3% compared to SPY -0.2%.
ELVN support price is $46.47 and resistance is $50.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.
